January 30, 2023 11:32 AM ESTUpdated February 7, 09:28 AM

#JPM23: Regulatory uncertainty? What about M&A? Data rule? Alessandro Maselli and John Carroll take out their crystal balls

John Carroll

Editor & Founder

Endpoints editor and founder John Carroll sat down the Catalent CEO Alessandro Maselli to talk about what’s ahead in 2023. Right or wrong, this covers …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

TRENDING NOW

#JPM23: Regulatory uncertainty? What about M&A? Data rule? Alessandro Maselli and John Carroll take out their crystal balls

John Carroll

Editor & Founder

Sign up to read this article for free.

NewAmsterdam aces Phase 3 trial, but investors are skeptical

Pfizer partners with two more Flagship biotechs on obesity, cancer

Post-Hoc: RFK vs. Vivek, and the future of US drug policy

FDA updates label of 33-year-old cancer drug with new dose and warning

Novo and Viking present new MASH data, but analysts remain confident in Madrigal's Rezdiffra

Are programs with compounded GLP-1s safe for your population?

#JPM23: Reg­u­la­to­ry un­cer­tain­ty? What about M&A? Da­ta rule? Alessan­dro Masel­li and John Car­roll take out their crys­tal balls

John Carroll

Editor & Founder

Sign up to read this article for free.

NewAms­ter­dam aces Phase 3 tri­al, but in­vestors are skep­ti­cal

Pfiz­er part­ners with two more Flag­ship biotechs on obe­si­ty, can­cer

Post-Hoc: RFK vs. Vivek, and the fu­ture of US drug pol­i­cy

FDA up­dates la­bel of 33-year-old can­cer drug with new dose and warn­ing

No­vo and Viking present new MASH da­ta, but an­a­lysts re­main con­fi­dent in Madri­gal's Rezd­if­fra

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

#JPM23: Regulatory uncertainty? What about M&A? Data rule? Alessandro Maselli and John Carroll take out their crystal balls

NewAmsterdam aces Phase 3 trial, but investors are skeptical

Pfizer partners with two more Flagship biotechs on obesity, cancer

Post-Hoc: RFK vs. Vivek, and the future of US drug policy

FDA updates label of 33-year-old cancer drug with new dose and warning

Novo and Viking present new MASH data, but analysts remain confident in Madrigal's Rezdiffra

Are programs with compounded GLP-1s safe for your population?